Intrinsic value of Egalet - EGLT

Previous Close

$1.01

  Intrinsic Value

$0.03

stock screener

  Rating & Target

str. sell

-97%

Previous close

$1.01

 
Intrinsic value

$0.03

 
Up/down potential

-97%

 
Rating

str. sell

We calculate the intrinsic value of EGLT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  -26.09
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  17
  27
  42
  63
  91
  129
  177
  237
  312
  401
  507
  629
  769
  927
  1,103
  1,297
  1,509
  1,738
  1,984
  2,247
  2,527
  2,822
  3,133
  3,459
  3,801
  4,158
  4,530
  4,917
  5,320
  5,739
  6,175
Variable operating expenses, $m
 
  88
  136
  203
  295
  416
  572
  768
  1,008
  1,298
  1,639
  2,035
  2,488
  2,999
  3,569
  4,196
  4,881
  5,622
  6,419
  7,270
  8,174
  9,129
  10,135
  11,191
  12,296
  13,450
  14,653
  15,907
  17,211
  18,567
  19,976
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  98
  88
  136
  203
  295
  416
  572
  768
  1,008
  1,298
  1,639
  2,035
  2,488
  2,999
  3,569
  4,196
  4,881
  5,622
  6,419
  7,270
  8,174
  9,129
  10,135
  11,191
  12,296
  13,450
  14,653
  15,907
  17,211
  18,567
  19,976
Operating income, $m
  -81
  -61
  -94
  -140
  -204
  -288
  -395
  -531
  -697
  -897
  -1,132
  -1,406
  -1,719
  -2,072
  -2,465
  -2,899
  -3,372
  -3,884
  -4,435
  -5,023
  -5,647
  -6,307
  -7,002
  -7,731
  -8,495
  -9,292
  -10,124
  -10,990
  -11,891
  -12,827
  -13,801
EBITDA, $m
  -77
  -55
  -84
  -126
  -183
  -258
  -355
  -476
  -625
  -804
  -1,016
  -1,262
  -1,543
  -1,859
  -2,212
  -2,601
  -3,026
  -3,486
  -3,980
  -4,507
  -5,068
  -5,660
  -6,283
  -6,938
  -7,623
  -8,338
  -9,085
  -9,862
  -10,670
  -11,511
  -12,385
Interest expense (income), $m
  0
  3
  1
  1
  2
  4
  6
  8
  11
  15
  20
  25
  32
  39
  47
  56
  66
  77
  89
  102
  116
  130
  146
  162
  179
  196
  215
  234
  254
  275
  297
Earnings before tax, $m
  -92
  -64
  -94
  -142
  -206
  -291
  -401
  -539
  -708
  -912
  -1,152
  -1,432
  -1,751
  -2,111
  -2,513
  -2,955
  -3,439
  -3,962
  -4,524
  -5,125
  -5,763
  -6,437
  -7,148
  -7,893
  -8,673
  -9,489
  -10,339
  -11,224
  -12,145
  -13,103
  -14,098
Tax expense, $m
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -91
  -64
  -94
  -142
  -206
  -291
  -401
  -539
  -708
  -912
  -1,152
  -1,432
  -1,751
  -2,111
  -2,513
  -2,955
  -3,439
  -3,962
  -4,524
  -5,125
  -5,763
  -6,437
  -7,148
  -7,893
  -8,673
  -9,489
  -10,339
  -11,224
  -12,145
  -13,103
  -14,098

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  87
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  115
  45
  69
  104
  150
  212
  291
  391
  514
  661
  835
  1,036
  1,267
  1,527
  1,817
  2,137
  2,486
  2,863
  3,269
  3,702
  4,163
  4,649
  5,161
  5,699
  6,262
  6,849
  7,462
  8,101
  8,765
  9,455
  10,173
Adjusted assets (=assets-cash), $m
  28
  45
  69
  104
  150
  212
  291
  391
  514
  661
  835
  1,036
  1,267
  1,527
  1,817
  2,137
  2,486
  2,863
  3,269
  3,702
  4,163
  4,649
  5,161
  5,699
  6,262
  6,849
  7,462
  8,101
  8,765
  9,455
  10,173
Revenue / Adjusted assets
  0.607
  0.600
  0.609
  0.606
  0.607
  0.608
  0.608
  0.606
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
  0.607
Average production assets, $m
  20
  31
  48
  72
  105
  148
  203
  272
  358
  460
  581
  722
  882
  1,063
  1,265
  1,488
  1,731
  1,993
  2,276
  2,578
  2,898
  3,237
  3,593
  3,968
  4,360
  4,769
  5,195
  5,640
  6,102
  6,583
  7,083
Working capital, $m
  68
  -30
  -47
  -70
  -102
  -144
  -198
  -265
  -349
  -448
  -566
  -703
  -860
  -1,037
  -1,233
  -1,450
  -1,687
  -1,943
  -2,218
  -2,513
  -2,825
  -3,155
  -3,503
  -3,867
  -4,249
  -4,648
  -5,064
  -5,497
  -5,948
  -6,417
  -6,904
Total debt, $m
  84
  14
  36
  67
  109
  165
  236
  326
  436
  569
  725
  907
  1,114
  1,349
  1,610
  1,897
  2,211
  2,551
  2,916
  3,306
  3,720
  4,158
  4,619
  5,103
  5,609
  6,138
  6,690
  7,265
  7,862
  8,484
  9,130
Total liabilities, $m
  110
  40
  62
  93
  135
  191
  262
  352
  462
  595
  751
  933
  1,140
  1,375
  1,636
  1,923
  2,237
  2,577
  2,942
  3,332
  3,746
  4,184
  4,645
  5,129
  5,635
  6,164
  6,716
  7,291
  7,888
  8,510
  9,156
Total equity, $m
  5
  4
  7
  10
  15
  21
  29
  39
  51
  66
  83
  104
  127
  153
  182
  214
  249
  286
  327
  370
  416
  465
  516
  570
  626
  685
  746
  810
  876
  946
  1,017
Total liabilities and equity, $m
  115
  44
  69
  103
  150
  212
  291
  391
  513
  661
  834
  1,037
  1,267
  1,528
  1,818
  2,137
  2,486
  2,863
  3,269
  3,702
  4,162
  4,649
  5,161
  5,699
  6,261
  6,849
  7,462
  8,101
  8,764
  9,456
  10,173
Debt-to-equity ratio
  16.800
  3.200
  5.240
  6.490
  7.270
  7.770
  8.110
  8.340
  8.490
  8.610
  8.690
  8.750
  8.790
  8.830
  8.860
  8.880
  8.900
  8.910
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.970
Adjusted equity ratio
  -2.929
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -91
  -64
  -94
  -142
  -206
  -291
  -401
  -539
  -708
  -912
  -1,152
  -1,432
  -1,751
  -2,111
  -2,513
  -2,955
  -3,439
  -3,962
  -4,524
  -5,125
  -5,763
  -6,437
  -7,148
  -7,893
  -8,673
  -9,489
  -10,339
  -11,224
  -12,145
  -13,103
  -14,098
Depreciation, amort., depletion, $m
  4
  6
  10
  14
  21
  30
  41
  54
  72
  92
  116
  144
  176
  213
  253
  298
  346
  399
  455
  516
  580
  647
  719
  794
  872
  954
  1,039
  1,128
  1,220
  1,317
  1,417
Funds from operations, $m
  -71
  -57
  -85
  -127
  -185
  -262
  -360
  -484
  -637
  -820
  -1,036
  -1,287
  -1,574
  -1,898
  -2,260
  -2,658
  -3,092
  -3,563
  -4,069
  -4,609
  -5,183
  -5,790
  -6,429
  -7,099
  -7,801
  -8,535
  -9,299
  -10,096
  -10,924
  -11,786
  -12,681
Change in working capital, $m
  2
  -11
  -17
  -23
  -32
  -42
  -54
  -68
  -83
  -100
  -118
  -137
  -157
  -177
  -197
  -217
  -237
  -256
  -275
  -294
  -312
  -330
  -348
  -365
  -382
  -399
  -416
  -433
  -451
  -469
  -487
Cash from operations, $m
  -73
  -46
  -68
  -104
  -154
  -220
  -307
  -417
  -554
  -720
  -918
  -1,150
  -1,418
  -1,722
  -2,063
  -2,441
  -2,856
  -3,307
  -3,794
  -4,315
  -4,871
  -5,460
  -6,081
  -6,735
  -7,420
  -8,136
  -8,884
  -9,663
  -10,474
  -11,317
  -12,194
Maintenance CAPEX, $m
  0
  -4
  -6
  -10
  -14
  -21
  -30
  -41
  -54
  -72
  -92
  -116
  -144
  -176
  -213
  -253
  -298
  -346
  -399
  -455
  -516
  -580
  -647
  -719
  -794
  -872
  -954
  -1,039
  -1,128
  -1,220
  -1,317
New CAPEX, $m
  -7
  -12
  -17
  -24
  -33
  -43
  -55
  -69
  -85
  -103
  -121
  -141
  -161
  -181
  -202
  -222
  -243
  -263
  -283
  -302
  -320
  -339
  -357
  -374
  -392
  -409
  -427
  -444
  -462
  -481
  -500
Cash from investing activities, $m
  49
  -16
  -23
  -34
  -47
  -64
  -85
  -110
  -139
  -175
  -213
  -257
  -305
  -357
  -415
  -475
  -541
  -609
  -682
  -757
  -836
  -919
  -1,004
  -1,093
  -1,186
  -1,281
  -1,381
  -1,483
  -1,590
  -1,701
  -1,817
Free cash flow, $m
  -24
  -62
  -91
  -138
  -200
  -284
  -391
  -527
  -693
  -894
  -1,131
  -1,407
  -1,723
  -2,079
  -2,477
  -2,916
  -3,396
  -3,916
  -4,475
  -5,072
  -5,707
  -6,378
  -7,085
  -7,828
  -8,605
  -9,417
  -10,264
  -11,146
  -12,064
  -13,019
  -14,011
Issuance/(repayment) of debt, $m
  21
  -70
  22
  31
  42
  56
  71
  90
  110
  133
  156
  182
  208
  234
  261
  288
  314
  340
  365
  390
  414
  438
  461
  484
  506
  529
  552
  574
  598
  621
  646
Issuance/(repurchase) of shares, $m
  0
  150
  97
  145
  211
  298
  409
  549
  720
  927
  1,170
  1,452
  1,774
  2,137
  2,542
  2,987
  3,473
  4,000
  4,565
  5,168
  5,809
  6,486
  7,199
  7,947
  8,730
  9,547
  10,400
  11,288
  12,211
  13,172
  14,170
Cash from financing (excl. dividends), $m  
  22
  80
  119
  176
  253
  354
  480
  639
  830
  1,060
  1,326
  1,634
  1,982
  2,371
  2,803
  3,275
  3,787
  4,340
  4,930
  5,558
  6,223
  6,924
  7,660
  8,431
  9,236
  10,076
  10,952
  11,862
  12,809
  13,793
  14,816
Total cash flow (excl. dividends), $m
  -2
  19
  27
  38
  52
  69
  89
  112
  137
  165
  195
  226
  259
  292
  325
  358
  391
  424
  455
  486
  516
  546
  575
  603
  631
  659
  687
  716
  745
  775
  805
Retained Cash Flow (-), $m
  84
  -150
  -97
  -145
  -211
  -298
  -409
  -549
  -720
  -927
  -1,170
  -1,452
  -1,774
  -2,137
  -2,542
  -2,987
  -3,473
  -4,000
  -4,565
  -5,168
  -5,809
  -6,486
  -7,199
  -7,947
  -8,730
  -9,547
  -10,400
  -11,288
  -12,211
  -13,172
  -14,170
Prev. year cash balance distribution, $m
 
  87
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -44
  -69
  -107
  -158
  -228
  -320
  -437
  -583
  -761
  -975
  -1,225
  -1,515
  -1,845
  -2,216
  -2,629
  -3,082
  -3,576
  -4,110
  -4,682
  -5,293
  -5,940
  -6,624
  -7,344
  -8,098
  -8,888
  -9,712
  -10,572
  -11,466
  -12,397
  -13,365
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  -43
  -64
  -93
  -130
  -177
  -232
  -295
  -364
  -437
  -511
  -582
  -647
  -702
  -744
  -772
  -783
  -778
  -757
  -721
  -673
  -614
  -550
  -481
  -412
  -346
  -283
  -227
  -177
  -135
  -101
Current shareholders' claim on cash, %
  100
  50.0
  14.3
  4.2
  1.3
  0.4
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

FINANCIAL RATIOS  of  Egalet (EGLT)

Valuation Ratios
P/E Ratio -0.3
Price to Sales 1.5
Price to Book 5.1
Price to Tangible Book
Price to Cash Flow -0.3
Price to Free Cash Flow -0.3
Growth Rates
Sales Growth Rate -26.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 75%
Cap. Spend. - 3 Yr. Gr. Rate 28.5%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 1680%
Total Debt to Equity 1680%
Interest Coverage 0
Management Effectiveness
Return On Assets -63.4%
Ret/ On Assets - 3 Yr. Avg. -73.1%
Return On Total Capital -77.8%
Ret/ On T. Cap. - 3 Yr. Avg. -102.6%
Return On Equity -193.6%
Return On Equity - 3 Yr. Avg. -177.9%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 76.5%
Gross Margin - 3 Yr. Avg. 54.5%
EBITDA Margin -517.6%
EBITDA Margin - 3 Yr. Avg. -953.7%
Operating Margin -476.5%
Oper. Margin - 3 Yr. Avg. -850.9%
Pre-Tax Margin -541.2%
Pre-Tax Margin - 3 Yr. Avg. -982.6%
Net Profit Margin -535.3%
Net Profit Margin - 3 Yr. Avg. -979.2%
Effective Tax Rate 1.1%
Eff/ Tax Rate - 3 Yr. Avg. 0.9%
Payout Ratio 0%

EGLT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EGLT stock intrinsic value calculation we used $17 million for the last fiscal year's total revenue generated by Egalet. The default revenue input number comes from 2016 income statement of Egalet. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EGLT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EGLT is calculated based on our internal credit rating of Egalet, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Egalet.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EGLT stock the variable cost ratio is equal to 323.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for EGLT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Egalet.

Corporate tax rate of 27% is the nominal tax rate for Egalet. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EGLT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EGLT are equal to 114.7%.

Life of production assets of 4.9 years is the average useful life of capital assets used in Egalet operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EGLT is equal to -111.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $5 million for Egalet - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 43.047 million for Egalet is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Egalet at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
NKTR Nektar Therape 55.05 0.02  str.sell
DEPO DepoMed 8.16 1.00  str.sell
DRRX Durect 0.990 0.00  str.sell
TEVA Teva Pharmaceu 17.30 58.78  str.buy

COMPANY NEWS

▶ ETFs with exposure to Egalet Corp. : December 5, 2017   [Dec-05-17 12:43PM  Capital Cube]
▶ EGLT: Impressive Prescription Growth; Revenues Should Follow   [Nov-22-17 03:00PM  Zacks Small Cap Research]
▶ ETFs with exposure to Egalet Corp. : November 20, 2017   [Nov-20-17 12:19PM  Capital Cube]
▶ ETFs with exposure to Egalet Corp. : November 9, 2017   [Nov-09-17 12:38PM  Capital Cube]
▶ Egalet Corporation to Host Earnings Call   [Nov-08-17 06:40AM  ACCESSWIRE]
▶ Egalet reports 3Q loss   [06:09AM  Associated Press]
▶ ETFs with exposure to Egalet Corp. : October 30, 2017   [Oct-30-17 11:43AM  Capital Cube]
▶ Egalet (EGLT): The Guardian of Misuse and Abuse   [Oct-24-17 09:00AM  Zacks Small Cap Research]
▶ ETFs with exposure to Egalet Corp. : October 20, 2017   [Oct-20-17 10:11AM  Capital Cube]
▶ ETFs with exposure to Egalet Corp. : October 9, 2017   [Oct-09-17 11:28AM  Capital Cube]
▶ Egalet to Present at Investor Conferences this Fall   [Sep-06-17 06:02AM  PR Newswire]
▶ Egalet reports 2Q loss   [Aug-09-17 10:03PM  Associated Press]
▶ Egalet trims non-sales workforce by 40%   [05:20PM  American City Business Journals]
▶ Egalet Stumbles Over FDA Complete Response Letter   [Jun-20-17 10:15AM  24/7 Wall St.]
▶ ETFs with exposure to Egalet Corp. : June 8, 2017   [Jun-08-17 01:33PM  Capital Cube]
▶ Patents piling up for Wayne maker of abuse-deterrent medicines   [Jun-05-17 02:40PM  American City Business Journals]
▶ ETFs with exposure to Egalet Corp. : May 26, 2017   [May-26-17 01:06PM  Capital Cube]
▶ ETFs with exposure to Egalet Corp. : May 15, 2017   [May-15-17 03:38PM  Capital Cube]
▶ Egalet reports 1Q loss   [May-10-17 06:22AM  Associated Press]
▶ Egalet to Participate in Spring Investor Conferences   [Apr-03-17 06:02AM  PR Newswire]
▶ Egalet Gets 4 New Patents for Guardian Technology   [Mar-23-17 11:05AM  at Investopedia]
▶ Nektar Pharma Opioid Drug Shows Promise In Phase 3   [Mar-20-17 01:41PM  at Investopedia]
Financial statements of EGLT
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.